 Liquidia Technologies, Inc. LQDA, a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT technology, announced it has entered into a definitive agreement to acquire RareGen, LLC, a portfolio company of PBM Capital, through an all-stock merger. Liquidia and RareGen will consolidate under a new holding company, to be named Liquidia Corporation, which is expected to trade on the Nasdaq Capital Market under the ticker symbol LQDA, as the successor to Liquidia Technologies. RareGen has a small, targeted sales force focused on PAH. 